Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19621396 | 0.74 | TSHR (0.36) | MAPK1TSHR | |
| SCHEMBL14484474 | 0.74 | TSHR (0.36) | MAPK1TSHR | |
| SCHEMBL296319 | 0.74 | TSHR (0.36) | MAPK1TSHR | |
| SCHEMBL14497138 | 0.74 | TSHR (0.36) | MAPK1TSHR | |
| SCHEMBL891743 | 0.74 | TSHR (0.36) | MAPK1TSHR | |
| SCHEMBL19621525 | 0.74 | TSHR (0.36) | MAPK1TSHR | |
| SCHEMBL8190473 | 0.71 | TSHR (0.32) | MAPK1TSHR | |
| SCHEMBL15445237 | 0.71 | TSHR (0.34) | MAPK1TSHR | |
| SCHEMBL14484267 | 0.69 | TSHR (0.33) | MAPK1TSHR | |
| SCHEMBL12964746 | 0.67 | TSHR (0.32) | MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MAPK1 1515/4885TSHR 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.